COMMUNIQUÉS West-GlobeNewswire

Canopy Rivers Announces Investment in Technology Driven Data Company Headset
08/01/2019
TORONTO, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV:RIV) is pleased to announce it has completed an equity investment in Headset, Inc. (“ Headset ”), a data and [...]
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV
08/01/2019
Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical [...]
CLS Signs Agreement with Siemens Healthineers to Secure Optimal Interfacing to the World Leading Portfolio of Magnetom MRI Scanners from Siemens Healthineers
08/01/2019
IRVINE, Calif. and LUND, Sweden, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) and Siemens Healthineers have signed an agreement that gives CLS the right to license the “Access-i” [...]
Integra LifeSciences Announces Preliminary Fourth Quarter 2018 Financial Results
08/01/2019
Preliminary Fourth Quarter 2018 Highlights: Fourth quarter 2018 reported revenue is expected to be at the higher end of the company’s previous guidance range of $378 million to $383 million; Organic revenue growth in [...]
MediPharm Labs Signs Large Multi-Year Cannabis Extraction Agreement With TerrAscend Marking Strong Start to 2019
08/01/2019
TORONTO, Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS; OTCQB: MLCPF) (the “ Company ” or “ MediPharm Labs ”), a specialized, research-driven cannabis extraction business, fully licensed under the [...]
Corrected Financial Calendar 2019
08/01/2019
January 8, 2019 Announcement no. 1 Corrected Financial Calendar 2019 DATE 2019 DESCRIPTION January 25, 2019 Quiet Period prior to the Annual Report begins (4 weeks) February 1, 2019 Deadline for shareholder proposals - [...]
Transactions in relation to share buyback program
08/01/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Vistin Pharma ASA : Update on Energy Trading business
08/01/2019
(Oslo, Norway, 8 January 2019) The Board of Directors of Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) has conducted a strategic review of the Energy Trading business following the development in the energy markets. [...]
Immuron Receives $1.19M R&D Tax Concession Refund
08/01/2019
MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax [...]
Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test
08/01/2019
Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency Initiates [...]
Update on Admission
08/01/2019
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Subscription to Raise $25m Oxford, UK, and Cambridge, MA, US, 8 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic [...]
Scheme becomes effective
08/01/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]
NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT
08/01/2019
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT Paris and Boston, January 8, 2019 - 7 [...]
NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏDE DANS L'ALLERGIE
08/01/2019
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏDE DANS L'ALLERGIE Paris et [...]
Nicox Reaches 50% Enrollment Threshold in U.S. Phase 2 Study with NCX 470 Ahead of Schedule
08/01/2019
Press Release Nicox Reaches 50% Enrollment Threshold in U.S. Phase 2 Study with NCX 470 Ahead of Schedule ............................................... January 8, 2019 - release at 7:30 am CET Sophia Antipolis, France [...]
Nicox atteint plus tôt que prévu le seuil de 50% de recrutement dans l'étude clinique de phase 2 avec le NCX 470 aux Etats-Unis
08/01/2019
Communiqué de presse Nicox atteint plus tôt que prévu le seuil de 50% de recrutement dans l'étude clinique de phase 2 avec le NCX 470 aux Etats-Unis ................................................. 8 janvier 2019 - [...]
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
08/01/2019
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered by multi-cell adhesion [...]
Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco
08/01/2019
NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial [...]
Scheme becomes effective
08/01/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]

Pages